61 related articles for article (PubMed ID: 17962202)
21. Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer.
Grootjans W; de Geus-Oei LF; Meeuwis AP; van der Vos CS; Gotthardt M; Oyen WJ; Visser EP
Eur Radiol; 2014 Dec; 24(12):3242-50. PubMed ID: 25097133
[TBL] [Abstract][Full Text] [Related]
22. FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.
van Gool MH; Aukema TS; Hartemink KJ; Valdés Olmos RA; van Tinteren H; Klomp HM
World J Radiol; 2014 Jul; 6(7):392-8. PubMed ID: 25071879
[TBL] [Abstract][Full Text] [Related]
23. CT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Johannesen HH; Nielsen D; Schou JV; Jensen BV; Høgdall EV; Hendel HW
Cancer Med; 2014 Oct; 3(5):1294-301. PubMed ID: 24941936
[TBL] [Abstract][Full Text] [Related]
24. Recent chemotherapy reduces the maximum-standardized uptake value of 18F-fluoro-deoxyglucose positron emission tomography in colorectal cancer.
Lee M; Yeum TS; Kim JW; Oh S; Lee SA; Moon HR; Choi YH; Han YM; Choi JM; Jang DK
Gut Liver; 2014 May; 8(3):254-64. PubMed ID: 24827621
[TBL] [Abstract][Full Text] [Related]
25. Monitoring of tumor response to Cisplatin using optical spectroscopy.
Spliethoff JW; Evers DJ; Jaspers JE; Hendriks BH; Rottenberg S; Ruers TJ
Transl Oncol; 2014 Apr; 7(2):230-9. PubMed ID: 24726234
[TBL] [Abstract][Full Text] [Related]
26. Positron emission tomography/computed tomography and biomarkers for early treatment response evaluation in metastatic colon cancer.
Engelmann BE; Loft A; Kjær A; Nielsen HJ; Gerds TA; Benzon EV; Brünner N; Christensen IJ; Hansson SH; Holländer NH; Kristensen MH; Löfgren J; Markova E; Sloth C; Højgaard L
Oncologist; 2014 Feb; 19(2):164-72. PubMed ID: 24451199
[TBL] [Abstract][Full Text] [Related]
27. Functional imaging biomarkers for assessing response to treatment in liver and lung metastases.
Bernardin L; O'Flynn EA; Desouza NM
Cancer Imaging; 2013 Dec; 13(4):482-94. PubMed ID: 24334562
[TBL] [Abstract][Full Text] [Related]
28. Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases.
Mertens J; De Bruyne S; Van Damme N; Smeets P; Ceelen W; Troisi R; Laurent S; Geboes K; Peeters M; Goethals I; Van de Wiele C
Eur J Nucl Med Mol Imaging; 2013 Aug; 40(8):1214-22. PubMed ID: 23636802
[TBL] [Abstract][Full Text] [Related]
29. Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
Hendlisz A; Golfinopoulos V; Deleporte A; Paesmans M; Mansy HE; Garcia C; Peeters M; Annemans L; Vandeputte C; Maetens M; Borbath I; Dresse D; Houbiers G; Fried M; Awada A; Piccart M; Laethem JL; Flamen P
BMC Cancer; 2013 Apr; 13():190. PubMed ID: 23587148
[TBL] [Abstract][Full Text] [Related]
30. (18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors.
Desar IM; Gilles R; van Herpen CM; Timmer-Bonte AJ; Cantarini MV; van der Graaf WT; Oyen WJ
World J Nucl Med; 2012 May; 11(2):65-9. PubMed ID: 23372439
[TBL] [Abstract][Full Text] [Related]
31. Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer.
Buvat I; Necib H; Garcia C; Wagner A; Vanderlinden B; Emonts P; Hendlisz A; Flamen P
Eur J Nucl Med Mol Imaging; 2012 Oct; 39(10):1628-34. PubMed ID: 22710958
[TBL] [Abstract][Full Text] [Related]
32. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.
De Bruyne S; Van Damme N; Smeets P; Ferdinande L; Ceelen W; Mertens J; Van de Wiele C; Troisi R; Libbrecht L; Laurent S; Geboes K; Peeters M
Br J Cancer; 2012 Jun; 106(12):1926-33. PubMed ID: 22596235
[TBL] [Abstract][Full Text] [Related]
33. Response evaluation of chemotherapy in metastatic colorectal cancer by contrast enhanced ultrasound.
Schirin-Sokhan R; Winograd R; Roderburg C; Bubenzer J; do Ó NC; Guggenberger D; Hecker H; Trautwein C; Tischendorf JJ
World J Gastroenterol; 2012 Feb; 18(6):541-5. PubMed ID: 22363120
[TBL] [Abstract][Full Text] [Related]
34. Desmoid tumour (aggressive fibromatosis) of the colon mimics malignancy on dual time-point 18F-FDG PET/CT imaging.
Makis W; Ciarallo A; Abikhzer G; Stern J; Laufer J
Br J Radiol; 2012 Feb; 85(1010):e37-40. PubMed ID: 22308225
[TBL] [Abstract][Full Text] [Related]
35. Molecular mechanism underlying the detection of colorectal cancer by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography.
Izuishi K; Yamamoto Y; Sano T; Takebayashi R; Nishiyama Y; Mori H; Masaki T; Morishita A; Suzuki Y
J Gastrointest Surg; 2012 Feb; 16(2):394-400. PubMed ID: 22065316
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma.
Gilles R; de Geus-Oei LF; Mulders PF; Oyen WJ
World J Urol; 2013 Aug; 31(4):841-6. PubMed ID: 21739122
[TBL] [Abstract][Full Text] [Related]
37. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
Brouquet A; Overman MJ; Kopetz S; Maru DM; Loyer EM; Andreou A; Cooper A; Curley SA; Garrett CR; Abdalla EK; Vauthey JN
Cancer; 2011 Oct; 117(19):4484-92. PubMed ID: 21446046
[TBL] [Abstract][Full Text] [Related]
38. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres.
Haug AR; Heinemann V; Bruns CJ; Hoffmann R; Jakobs T; Bartenstein P; Hacker M
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1037-45. PubMed ID: 21308371
[TBL] [Abstract][Full Text] [Related]
39. Comparison of different SUV-based methods for response prediction to neoadjuvant radiochemotherapy in locally advanced rectal cancer by FDG-PET and MRI.
Herrmann K; Bundschuh RA; Rosenberg R; Schmidt S; Praus C; Souvatzoglou M; Becker K; Schuster T; Essler M; Wieder HA; Friess H; Ziegler SI; Schwaiger M; Krause BJ
Mol Imaging Biol; 2011 Oct; 13(5):1011-9. PubMed ID: 20936364
[TBL] [Abstract][Full Text] [Related]
40. Methodological considerations in quantification of oncological FDG PET studies.
Vriens D; Visser EP; de Geus-Oei LF; Oyen WJ
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1408-25. PubMed ID: 19936745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
